Roles of polymorphism in promoter region of miR-34b/c in cancer: a Meta analysis

Abstract

Abstract:Objective To investigate the association between the genetic variant in the promoter region of miR34b/c and cancer risk. MethodsDatabases such as PubMed、EMBase、Wanfang、VIP、CNKI and so on were searched comprehensively. Based on the including and excluding criteria, literatures that were eligible were screened and data were retrieved. Meta analysis was performed by RevMan 5.1 software. ResultsThrough searching and manually searching relevant references, a total of 9 articles with 10 independent studies were included. No significant associations were detected in C vs T, CC vs TT, CC+CT vs TT and CC vs CT+TT comparison models. However, in the CT vs TT comparison model, the result showed a significant association (Z=2.33, P=0.02). Meanwhile, subgroup analysis of hepatocellular carcinoma and colorectal cancer both showed significant associations with the polymorphism, with C vs T (OR=1.11, Z=2.10, P=0.04), CT vs TT (Z=2.40, P=0.02), CC+CT vs TT (Z=2.45, P=0.01) and CC vs TT (OR=0.66, Z=2.43, P=0.02）, CC vs CT+TT (OR=0.67, Z=2.40, P=0.02) respectively. The C allele increased significantly the susceptibility of hepatocellular carcinoma, and the CC genotype reduced significantly the susceptibility of colorectal cancer. ConclusionThe genetic variant in the promoter region of miR34b/c rs4938723 T>C is significantly associated with the susceptibility of hepatocellular carcinoma and colorectal cancer.

Key words:Neoplasms,Polymorphism, genetic,Meta-analysis,miR-34b/c

Zeng Hui, Zeng Tuo, Long Xinghua. Roles of polymorphism in promoter region of miR-34b/c in cancer: a Meta analysis[J]. Journal of International Oncology, 2015, 42(1): 27-31.

References

［1］ He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network［J］. Nature, 2007, 447(7148): 1130-1134. ［2］ Wang JX, Jiao JQ, Li Q, et al. MiR499 regulates mitochondrial dynamics by targeting calcineurin and dynaminrelated protein1［J］. Nat Med, 2011, 17(1): 71-78. ［3］ Hu Z, Chen J, Tian T, et al. Genetic variants of miRNA sequences and nonsmall cell lung cancer survival［J］. J Clin Invest, 2008, 118(7): 2600-2608. ［4］ Stang A. Critical evaluation of the NewcastleOttawa scale for the assessment of the quality of nonrandomized studies in metaanalyses［J］. Eur J Epidemiol, 2010, 25(9): 603-605. ［5］ Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses［J］. BMJ, 2003, 327(7414): 557-560. ［6］ DerSimonian R, Kacker R. Randomeffects model for metaanalysis of clinical trials: an update［J］. Contemp Clin Trials, 2007, 28(2): 105-114. ［7］ Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis［J］. Stat Med, 2002, 21(11): 1539-1558. ［8］ Bensen JT, Tse CK, Nyante SJ, et al. Association of germline microRNA SNPs in premiRNA flanking region and breast cancer risk and survival: the carolina breast cancer study［J］. Cancer Causes Control, 2013, 24(6): 1099-1109. ［9］ Gao LB, Li LJ, Pan XM, et al. A genetic variant in the promoter region of miR34b/c is associated with a reduced risk of colorectal cancer［J］. Biol Chem, 2013, 394(3): 415-420. ［10］ Han Y, Pu R, Han X, et al. Associations of primiR34b/c and premiR196a2 polymorphisms and their multiplicative interactions with hepatitis B virus mutations with hepatocellular carcinoma risk［J］. PLoS One, 2013, 8(3): e58564. ［11］ Li L, Wu J, Sima X, et al. Interactions of miR34b/c and TP53 polymorphisms on the risk of nasopharyngeal carcinoma［J］. Tumour Biol, 2013, 34(3): 1919-1923. ［12］ Oh J, Kim JW, Lee BE, et al. Polymorphisms of the primiR34b/c promoter and TP53 codon 72 are associated with risk of colorectal cancer［J］. Oncol Rep, 2014, 31(2): 995-1002. ［13］ Son MS, Jang MJ, Jeon YJ, et al. Promoter polymorphisms of primiR34b/c are associated with hepatocellular carcinoma［J］. Gene, 2013, 524(2): 156-160. ［14］ Xu Y, Liu L, Liu J, et al. A potentially functional polymorphism in the promoter region of miR34b/c is associated with all increased risk for primary hepatocellular carcinoma［J］. Int J Cancer, 2011, 128(2): 412-417. ［15］ Yin J, Wang X, Zheng L, et al. HsamiR34b/c rs4938723 T>C and hsamiR423 rs6505162 C>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population［J］. PLoS One, 2013, 8(11): e80570. ［16］ Zhang S, Qian J, Cao Q, et al. A potentially functional polymorphism in the promoter region of miR34b/c is associated with renal cell cancer risk in a Chinese population［J］. Mutagenesis, 2014, 29(2): 149-154. ［17］ Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin4 encodes small RNAs with antisense complementarity to lin14［J］. Cell, 1993, 75(5): 843-854. ［18］ Lee Y, Ahn C, Han J, et al. The nuclear RNase Ⅲ Drosha initiates microRNA processing［J］. Nature, 2003, 425(6956): 415-419. ［19］ Kong W, Zhao JJ, He L, et al. Strategies for profiling microRNA expression［J］. J Cell Physiol, 2009, 218(1): 22-25. ［20］ Hutvágner G, McLachlan J, Pasquinelli AE, et al. A cellular function for the RNAinterference enzyme Dicer in the maturation of the let-7 small temporal RNA ［J］. Science, 2001, 293(5531): 834-838. ［21］ Dahiya N, ShermanBaust CA, Wang TL, et al. MicroRNA expression and identification of putative miRNA targets in ovatian cancer［J］. PLoS One, 2008, 3(6): e2436. ［22］ Kogo R, Mimori K, Tanaka F, et al. Clinical significance of miR146a in gastric cancer cases［J］. Clin Cancer Res, 2011, 17(13): 4277-4284. ［23］ Yu F, Yao H, Zhu P, et al. Let7 regulates self renewal and tumorigenicity of breast cancer cells［J］. Cell, 2007, 131(6): 1109-1123. ［24］ Kumar MS, Lu J, Mercer KL, et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis［J］. Nat Genet, 2007, 39(5): 673-677. ［25］ Guo Z, Wu C, Wang X, et al. A polymorphism at the miR502 binding site in the 3′untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome［J］. Int J Cancer, 2012, 131(6):1318-1322. ［26］ Liu AM, Zhang C, Burchard J, et al. Global regulation on microRNA in hepatitis B virusassociated hepatocellular carcinoma［J］. OMICS, 2011, 15(3): 187-191. ［27］郭哲, 向邦德. 微小RNA在肝细胞癌及肝癌干细胞中的作用［J］. 国际肿瘤学杂志, 2011, 38(9): 680-683. ［28］张灵敏, 王亚旭. 微小RNA与结直肠癌［J］. 国际肿瘤学杂志, 2014, 41(4)：290-293.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.